Top News

Eli Lilly Stock Falls as Mounjaro Sales Fall Short. Earnings Still Crushed.


Eli Lilly Stock Falls as Obesity Drug Sales Disappoint. | Barron’s

Eli Lilly

stock was falling Thursday as sales in the pharmaceutical company’s much-hyped obesity drug came up short. Fourth-quarter earnings, however, did crush estimates.

Shares in

Eli Lilly

(ticker: LLY) fell 2.9% in premarket trading. Futures tracking the

S&P 500

were rising 0.5%, by comparison.

Eli Lilly Dives After A ‘Bump In The Road’ Shakes Its Newest Diabetes Drug

Previous article

Hanesbrands Shares Plunge After Dividend Cut, Gloomy Earnings and Forecast

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Top News